BidaskClub lowered shares of Xencor, Inc. (NASDAQ:XNCR) from a hold rating to a sell rating in a research note released on Monday morning.

A number of other equities analysts have also weighed in on XNCR. Canaccord Genuity reissued a buy rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Xencor from a hold rating to a sell rating in a research report on Friday. Finally, Wedbush reissued an outperform rating and issued a $29.00 price objective on shares of Xencor in a research report on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Xencor currently has an average rating of Hold and a consensus price target of $29.33.

Xencor (NASDAQ XNCR) traded up 0.5668% during mid-day trading on Monday, hitting $21.7526. 41,949 shares of the stock traded hands. Xencor has a 12-month low of $18.45 and a 12-month high of $29.38. The company’s market cap is $1.02 billion. The firm’s 50-day moving average is $22.61 and its 200-day moving average is $23.06.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The business had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Equities research analysts expect that Xencor will post ($1.17) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (XNCR) Lowered to Sell at BidaskClub” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/15/xencor-inc-xncr-lowered-to-sell-at-bidaskclub.html.

In related news, major shareholder John S. Stafford III purchased 1,500 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was purchased at an average price of $19.67 per share, with a total value of $29,505.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce L. A. Carter sold 12,400 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $22.19, for a total transaction of $275,156.00. Following the transaction, the director now directly owns 83,344 shares of the company’s stock, valued at approximately $1,849,403.36. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 34,500 shares of company stock valued at $719,655 and have sold 34,766 shares valued at $739,408. Corporate insiders own 4.14% of the company’s stock.

A number of institutional investors have recently modified their holdings of XNCR. Equitec Specialists LLC bought a new position in shares of Xencor during the second quarter valued at approximately $116,000. SG Americas Securities LLC raised its position in shares of Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the period. Legal & General Group Plc raised its position in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the period. Airain ltd bought a new position in shares of Xencor during the first quarter valued at approximately $213,000. Finally, Citadel Advisors LLC bought a new position in shares of Xencor during the second quarter valued at approximately $224,000. 73.53% of the stock is owned by hedge funds and other institutional investors.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.